# TRex Bio Inc. (TRXB) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $13.73, market value $377 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). TRex Bio Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 9.6×**. Each dollar of revenue is priced at 9.6×.
- **Free-cash-flow yield: -11.0%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -6.1%**. Operating margin is negative: the business loses money before interest and tax.
- **Return on equity: 37.8%**. 37.8% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 1.5%**. Return on all capital, debt included, is 1.5%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -4.3%**. Each dollar of assets produces -4.3% of profit.

## Growth
- **EPS growth (1 yr): -294.6%**. Earnings per share fell 294.6%.

## Financial health
- **Current ratio: 14.30** (quick 14.30). Current assets cover the next year's liabilities 14.30 times.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. TRex Bio Inc. does not currently pay a dividend, but it returned -0.1% of its market value through buybacks over the last year.

## Price and momentum
- **From 52-week high: -17.1%** (4.8% above the low). Trading 17% below its 52-week high.
- **RSI (14-day): 48**. An RSI of 48 is neutral.

Live score and charts: https://foliofundamentals.com/analyzer?s=TRXB · Page: https://foliofundamentals.com/stocks/trxb

Not investment advice.